1. Home
  2. Analysis
  3. Kisqali
  4. Methotrexate

Kisqali and Methotrexate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Kisqali (ribociclib succinate) and Methotrexate (methotrexate sodium). Common drug interactions include hepatotoxicity among females.

The phase IV clinical study analyzes what interactions people have when they take Kisqali and Methotrexate. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Kisqali?

Kisqali has active ingredients of ribociclib succinate. eHealthMe is studying from 25,049 Kisqali users. Check the latest studies of Kisqali.

What is Methotrexate?

Methotrexate has active ingredients of methotrexate sodium. It is often used in rheumatoid arthritis. eHealthMe is studying from 604,312 Methotrexate users. Check the latest studies of Methotrexate.

On Jul, 12, 2026

14 people who take Kisqali and Methotrexate together, and have interactions are studied.

Kisqali and Methotrexate drug interactions.

What are the common drug interactions of Kisqali and Methotrexate, by gender? *:

female:

  1. Hepatotoxicity (chemical-driven liver damage)
  2. Anaemia (lack of blood)
  3. Back pain
  4. Body temperature decreased
  5. Conjunctival hyperaemia (congestion of conjunctival vessels)
  6. Contusion (a type of hematoma of tissue in which capillaries)
  7. Drug ineffective
  8. Eye discharge
  9. Eye haemorrhage (bleeding in the eye)
  10. Eye pain

male:

n/a

What are the common drug interactions of Kisqali and Methotrexate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Abdominal pain upper
  2. Dizziness
  3. Fatigue (feeling of tiredness)
  4. Headache (pain in head)
  5. Nausea (feeling of having an urge to vomit)

60+:

  1. Hepatotoxicity (chemical-driven liver damage)
  2. Anaemia (lack of blood)
  3. Conjunctival hyperaemia (congestion of conjunctival vessels)
  4. Contusion (a type of hematoma of tissue in which capillaries)
  5. Drug ineffective
  6. Eye discharge
  7. Eye haemorrhage (bleeding in the eye)
  8. Eye pain
  9. Fall
  10. Fatigue (feeling of tiredness)

What are the existing conditions these people have? *

  1. Breast Cancer Metastatic: 8 people, 57.14%
  2. Breast Cancer: 3 people, 21.43%
  3. Pain: 1 person, 7.14%
  4. Neoplasm Malignant (cancer tumour): 1 person, 7.14%
  5. Headache (pain in head): 1 person, 7.14%
  6. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Kisqali and Methotrexate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Kisqali and Methotrexate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Kisqali:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Methotrexate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Kisqali and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Methotrexate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on ribociclib succinate and methotrexate sodium (the active ingredients of Kisqali and Methotrexate, respectively), and Kisqali and Methotrexate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.